What is Silo Pharma?
Silo Pharma Inc. operates as a developmental stage biopharmaceutical entity dedicated to the creation of novel therapeutics for complex, underserved medical conditions. The company maintains a dual-focus strategy, integrating conventional pharmaceutical development with innovative psychedelic formulations. Its research portfolio specifically targets high-burden areas such as post-traumatic stress disorder (PTSD), stress-induced psychiatric disorders, chronic pain management, and various central nervous system (CNS) diseases. By addressing these critical gaps in the current standard of care, Silo Pharma aims to redefine treatment paradigms for patients suffering from debilitating neurological and psychological ailments.
How much funding has Silo Pharma raised?
Silo Pharma has raised a total of $8.3M across 2 funding rounds:
Share Placement
$4.3M
Private Equity
$4M
Share Placement (2021): $4.3M, investors not publicly disclosed
Private Equity (2026): $4M, investors not publicly disclosed
Key Investors in Silo Pharma
Undisclosed Investor
An institutional capital provider specializing in long-term growth equity and strategic biopharmaceutical investments.
Undisclosed Investor
A financial entity focused on supporting developmental stage life sciences companies through targeted equity placements.
Undisclosed Investor
An investment firm dedicated to funding innovative CNS research and novel therapeutic modalities.
What's next for Silo Pharma?
With the successful closure of this major enterprise-level funding, Silo Pharma is expected to prioritize the expansion of its clinical trial infrastructure and the acceleration of its lead therapeutic candidates. The strategic deployment of this capital will likely focus on navigating regulatory pathways and scaling manufacturing capabilities for its proprietary psychedelic formulations. As the company moves deeper into its development lifecycle, stakeholders will be monitoring the progression of its CNS pipeline and the potential for strategic partnerships that could further validate its unique therapeutic platform in the competitive biopharmaceutical landscape.
See full Silo Pharma company page
